March 4, 2024 (press release) –
![]() We are pleased to invite investors and analysts to participate in our virtual event on Monday, 11 March 2024, highlighting key data presented at 2024 Muscular Dystrophy Association (MDA) and Alzheimer's & Parkinson's Diseases (AD/PD) conferences. 15:00 – 16:30 CET / 14:00 – 15:30 GMT 10:00 – 11:30 AM EDT / 07:00 – 08:30 AM PDT The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 14:00 CET on the day of the event. >click here Agenda Welcome Bruno Eschli, Head of Investor Relations Neurology franchise update Paulo Fontoura, Senior Vice President and Global Head of Neuroscience, Immunology, Ophthalmology, Cardiometabolic, Infectious and Rare Diseases Clinical Development Review of key EMBARK data presented at MDA Alex Murphy, Senior Clinical Director Review of key trotinemab and prasinezumab data presented at AD/PD Azad Bonni, MD, PhD, Senior Vice President and Global Head of Neuroscience & Rare Diseases, Roche Pharma Research & Early Development Q&A Access to virtual event (pre-registration required) Please pre-register for our webinar here.* Should you be unable to register for the webinar due to your company IT policy, please send an email to investor.relations@roche.com. A replay of the webinar will be available via > ir.roche.com *privacy notice Best regards, |
||
Bruno Eschli Head of Investor Relations |
Loren Kalm Head of Investor Relations, North America |
Roche Investor Relations | |
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
|
Investor Relations North America | |
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.